Opportunity Information: Apply for TI 13 003
Apply for TI 13 003
- The Substance Abuse Mental Health Services Adminis. in the health sector is offering a public funding opportunity titled "FY 2013 Cooperative Agreement for the Physician Clinical Support System Medication Assisted Treatment" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243 Substance Abuse and Mental Health ServicesProjects of Regional and National Significance.
- This funding opportunity was created on Feb 13, 2013 and posted on Feb 13, 2013.
- Applicants must submit their applications by Apr 1, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility is limited to the national professional medical organizations authorized by the Drug Addiction Treatment Act of 2000 (DATA) to carry out the training of physicians desiring to prescribe and/or dispense FDA approved schedule III medications for the treatment of addictive disorders. These are the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association. Any of these entities may apply individually they may also apply as a consortium comprised of all or several of the eligible organizations. If a consortium is formed for this purpose, a single organization in the consortium must be the legal applicant, the recipient of the award, and the entity legally responsible for satisfying the grant requirements. If a consortium submits an application, the application must include a written agreement outlining the roles and responsibilities of each participating national professional medical organization. This agreement must be signed by an authorized official of each member of the consortium and attached to the application in Attachment 3 Roles and Responsibilities of Participating National Professional Medical Organizations. There is a serious public health issue involving the abuse, misuse, non medical use and concomitant morbidity and mortality associated with the increased availability of opioids for the treatment of acute pain, chronic pain and opioid related addiction. While these medications are mainly obtained legally through prescriptions, SAMHSA surveys indicate significant amounts are obtained through theft and other forms of diversion. In addition, SAMHSA recognizes the difficulty in assessing patients for appropriate opioid prescribing and the limited training that physicians, psychiatrists, and dentists may receive during their formal, specialized training. Moreover, licensed physicians, who have completed their formal training, lack adequate mentoring, continuing medical education, and other resources to evaluate patients and prescribe opioid analgesics appropriately. To address this public health problem in a timely manner, SAMHSA is limiting eligibility for this cooperative agreement to the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association. These organizations have extensive experience in providing educational and other support services to their members. As such, SAMHSA believes they are uniquely qualified to meet the requirements outlined in this announcement because they have the experience, infrastructure and capacity in place to expeditiously begin program activities. The statutory authority for this program prohibits grants to for profit agencies.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The FY 2013 Cooperative Agreement for the Physician Clinical Support System - Medication Assisted Treatment (PCSS-MAT) was a SAMHSA/CSAT funding opportunity designed to strengthen and expand a national physician training and mentoring infrastructure focused on treating opioid use disorder with FDA-approved medications. It builds directly on SAMHSA's earlier Physician Clinical Support System - Buprenorphine (PCSS-B), which primarily supported clinicians using buprenorphine in office-based settings. Under this FY 2013 program, the intent was to broaden the scope from buprenorphine alone to include all three FDA-approved medication options for opioid addiction treatment: buprenorphine (including buprenorphine/naloxone), methadone, and extended-release injectable naltrexone (Vivitrol). The overall aim was practical: increase clinician competence, confidence, and access to expert support so more patients can receive safe, evidence-based medication assisted treatment (MAT), especially in real-world primary care and opioid treatment program environments where adoption can be slowed by lack of training, uncertainty, and perceived complexity.
A central theme of the announcement is that opioid addiction treatment requires more than simply making medications available; it also requires a well-prepared clinical workforce. SAMHSA highlights that while buprenorphine prescribing had grown substantially, use of extended-release injectable naltrexone remained relatively low, in part because many primary care physicians did not receive enough education on opioid use disorder, on how to select appropriate patients, or on the specific clinical steps needed for naltrexone initiation after detoxification. The grant therefore emphasizes up-to-date, evidence-based education and consultation to address both basic and advanced clinical issues, including induction and maintenance strategies, relapse prevention, patient selection, safety considerations, and management of complex cases. It also explicitly recognizes that co-occurring medical and psychiatric conditions are common and can complicate treatment, so the program was expected to help clinicians navigate comorbidities that frequently accompany opioid use disorders.
The mechanism was a cooperative agreement, meaning SAMHSA anticipated an active federal role alongside the grantee in shaping and overseeing implementation. The program was structured to expand training capacity and provide a national mentoring network offering clinical updates, evidence-based outcomes, and multiple training formats and technologies. The target audience included office-based physicians, clinicians seeking to integrate addiction treatment into primary care, and medical professionals working in opioid treatment programs, with the broader objective of reducing resistance and practical barriers that keep effective pharmacologic treatment from being more widely adopted. By organizing training and consultation through established professional and specialty organizations, the project was meant to deliver credible guidance at scale and translate evolving research and best practices into routine clinical decision-making.
The opportunity also situates PCSS-MAT within SAMHSA's broader policy and public health goals. It is aligned with SAMHSA's Strategic Initiative on the Prevention of Substance Abuse and Mental Illness, including an explicit focus on reducing prescription drug misuse and abuse by educating current and future prescribers about appropriate prescribing practices for pain medications and other drugs with abuse potential. In other words, while the immediate focus is treatment of opioid addiction with methadone, buprenorphine, and naltrexone, the workforce development approach is also intended to improve prescribing quality and reduce downstream harms such as misuse, diversion, morbidity, and mortality associated with opioids. The announcement references Healthy People 2020's Substance Abuse topic area as another framework supporting the program's prevention and treatment goals.
Funding details were straightforward and concentrated. SAMHSA anticipated making one award with an estimated total funding amount of $1,000,000, and an award ceiling of $1,000,000 (with no specified minimum). There was no cost sharing or matching requirement. The opportunity was posted February 13, 2013, with an application deadline of April 1, 2013, and it was archived May 1, 2013. The CFDA listing included 93.243 (SAMHSA Projects of Regional and National Significance), and the activity category was health.
Eligibility was intentionally narrow due to the urgency of the public health issue and the need for immediate national-scale capacity. Applicants had to be national professional medical organizations authorized under the Drug Addiction Treatment Act of 2000 (DATA 2000) to conduct physician training for prescribing and/or dispensing FDA-approved schedule III medications for addiction treatment. The eligible entities listed were the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association. These organizations could apply individually or as a consortium, but if a consortium applied, one organization had to serve as the legal applicant and assume responsibility for grant compliance, and the application had to include a written, signed agreement specifying each partner's roles and responsibilities. The announcement also notes that statutory authority prohibited awards to for-profit agencies. This restricted eligibility reflects SAMHSA's view that these organizations already had the infrastructure, reach, and educational experience needed to rapidly deliver training, mentoring, and continuing education to a large clinician audience.
Finally, the grant is authorized under Section 509 of the Public Health Service Act, as amended, and is framed as a direct response to the broader opioid crisis dynamics described in the announcement: increased opioid availability for pain treatment, diversion and non-medical use, and the difficulty clinicians face in assessing patients and prescribing opioids appropriately with limited formal training and limited ongoing mentorship. The contact listed for access issues was Eileen Bermudez at SAMHSA in Rockville, Maryland, with a phone number and email provided in the notice.
Frequently Asked Questions (FAQs) - FY 2013 PCSS-MAT Cooperative Agreement
What is the FY 2013 PCSS-MAT cooperative agreement?
The FY 2013 Cooperative Agreement for the Physician Clinical Support System - Medication Assisted Treatment (PCSS-MAT) was a SAMHSA/CSAT funding opportunity to strengthen and expand a national physician training and mentoring infrastructure focused on treating opioid use disorder using FDA-approved medications.
What was the main purpose of PCSS-MAT?
The purpose was to increase clinician competence and confidence, expand access to expert consultation and mentoring, and reduce practical barriers to delivering safe, evidence-based medication assisted treatment (MAT) in real-world clinical settings.
How is PCSS-MAT different from the earlier PCSS-B program?
PCSS-MAT builds directly on SAMHSA's Physician Clinical Support System - Buprenorphine (PCSS-B). PCSS-B primarily supported clinicians using buprenorphine in office-based settings, while PCSS-MAT broadened the scope to cover all three FDA-approved medication options for opioid addiction treatment.
Which medications were included under PCSS-MAT?
The program expanded the focus beyond buprenorphine alone to include all three FDA-approved medications for opioid addiction treatment: buprenorphine (including buprenorphine/naloxone), methadone, and extended-release injectable naltrexone (Vivitrol).
Why did the funding opportunity emphasize training and mentoring rather than medication access alone?
SAMHSA emphasized that effective opioid addiction treatment requires a well-prepared clinical workforce. The announcement highlights that adoption can be slowed by limited training, uncertainty, perceived complexity, and lack of ongoing mentorship and expert support, even when medications are available.
What clinical topics was the program expected to address?
The opportunity emphasized up-to-date, evidence-based education and consultation on both basic and advanced issues, including induction and maintenance strategies, relapse prevention, patient selection, safety considerations, and management of complex cases.
Did the opportunity address co-occurring conditions?
Yes. The announcement explicitly recognized that co-occurring medical and psychiatric conditions are common and can complicate treatment, so the program was expected to help clinicians navigate comorbidities frequently accompanying opioid use disorders.
What does it mean that this funding mechanism was a cooperative agreement?
A cooperative agreement means SAMHSA anticipated an active federal role alongside the grantee in shaping and overseeing implementation, rather than a more hands-off approach typical of some grants.
What kinds of training and support approaches were envisioned?
The program was structured to expand training capacity and provide a national mentoring network offering clinical updates, evidence-based outcomes, and multiple training formats and technologies. The intent was to translate evolving research and best practices into routine clinical decision-making at scale.
Who was the target audience for the training and mentoring supported by this award?
The target audience included office-based physicians, clinicians seeking to integrate addiction treatment into primary care, and medical professionals working in opioid treatment programs.
Why did SAMHSA highlight extended-release injectable naltrexone specifically?
The announcement noted that use of extended-release injectable naltrexone remained relatively low, in part because many primary care physicians lacked sufficient education on opioid use disorder, patient selection, and the clinical steps required for naltrexone initiation after detoxification.
How did this opportunity connect to SAMHSA's broader policy goals?
PCSS-MAT was aligned with SAMHSA's Strategic Initiative on the Prevention of Substance Abuse and Mental Illness, including a focus on reducing prescription drug misuse and abuse by educating current and future prescribers about appropriate prescribing practices for pain medications and other drugs with abuse potential.
Did the program relate to Healthy People 2020?
Yes. The announcement referenced Healthy People 2020's Substance Abuse topic area as a framework supporting the program's prevention and treatment goals.
How many awards did SAMHSA anticipate making under this opportunity?
SAMHSA anticipated making one award.
What was the total estimated funding amount?
The estimated total funding amount was $1,000,000.
What was the award ceiling?
The award ceiling was $1,000,000.
Was there a minimum award amount specified?
No minimum award amount was specified in the information provided.
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement.
What were the key dates for this funding opportunity?
The opportunity was posted on February 13, 2013, with an application deadline of April 1, 2013. It was archived on May 1, 2013.
What CFDA program number was associated with this opportunity?
The CFDA listing included 93.243 (SAMHSA Projects of Regional and National Significance).
What was the activity category for this opportunity?
The activity category was health.
Who was eligible to apply?
Eligibility was limited to national professional medical organizations authorized under the Drug Addiction Treatment Act of 2000 (DATA 2000) to conduct physician training for prescribing and/or dispensing FDA-approved schedule III medications for addiction treatment.
Which organizations were listed as eligible applicants?
The eligible entities listed were the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, and the American Psychiatric Association.
Could an application be submitted by a consortium?
Yes. These organizations could apply individually or as a consortium. If a consortium applied, one organization had to serve as the legal applicant and assume responsibility for grant compliance.
What documentation was required for a consortium application?
The application had to include a written, signed agreement specifying each partner's roles and responsibilities.
Were for-profit agencies eligible to receive an award?
No. The announcement stated that statutory authority prohibited awards to for-profit agencies.
Why was eligibility so narrow?
The announcement described the eligibility limits as driven by urgency and the need for immediate national-scale capacity, reflecting SAMHSA's view that the listed organizations already had the infrastructure, reach, and educational experience to deliver training and mentoring to a large clinician audience.
What law authorized this cooperative agreement?
The grant was authorized under Section 509 of the Public Health Service Act, as amended.
What broader public health problem was this opportunity responding to?
The opportunity was framed as a response to opioid crisis dynamics described in the announcement, including increased opioid availability for pain treatment, diversion and non-medical use, and the difficulty clinicians face in assessing patients and prescribing opioids appropriately with limited formal training and limited ongoing mentorship.
Who was listed as the contact for access issues?
The contact listed for access issues was Eileen Bermudez at SAMHSA in Rockville, Maryland, with a phone number and email provided in the notice.
Browse more opportunities from the same agency: Substance Abuse Mental Health Services Adminis.
Browse more opportunities from the same category: Health
Next opportunity: Grants to Expand Substance Abuse Treatment Capacity In Adult, Juvenile, and Family Drug Courts (Short Title SAMHSA Treatment Drug Courts)
Previous opportunity: Promoting Adolescent Health through School Based HIV/STD Prevention and School Based Surveillance
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for TI 13 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (TI 13 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Grants to Expand Substance Abuse Treatment Capacity In Adult, Juvenile, and Family Drug Courts (Short Title SAMHSA Treatment Drug Courts) Apply for TI 13 005 Funding Number: TI 13 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $325,000 |
| Early Childhood Comprehensive SystemsBuilding Health Through Integration Apply for HRSA 13 177 Funding Number: HRSA 13 177 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Targeted Capacity Expansion Substance Abuse Treatment for Racial/Ethnic Minority Women at High Risk for HIV/AIDS (TCE HIV Minority Women) Apply for TI 13 011 Funding Number: TI 13 011 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $520,000 |
| National Center for Family/Professional Partnerships Apply for HRSA 13 206 Funding Number: HRSA 13 206 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Cooperative Agreements to Benefit Homeless Individuals for States (CABHI States) Apply for TI 13 004 Funding Number: TI 13 004 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $711,818 |
| Cooperative Agreements for State Adolescent Treatment Enhancement and Dissemination Apply for TI 13 014 Funding Number: TI 13 014 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $950,000 |
| Ryan White HIV/AIDS Program Part D Grants for Coordinated HIV Services and Access to Research for Women, Infants, Children, and Youth (WICY) Limited Competitive Service Areas (Georgia, Louisiana, and Western Pennsylvania) Apply for HRSA 13 264 Funding Number: HRSA 13 264 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Flex Rural Veterans Health Access Program Apply for HRSA 13 246 Funding Number: HRSA 13 246 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| HIV Early Intervention Services (EIS) Program Limited Competitive Service Areas (Brooklyn, NY, and Boston, MA) Apply for HRSA 13 274 Funding Number: HRSA 13 274 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Prehospital Evidence Based Guidelines Strategy Apply for DTNH22 13 R 00705 Funding Number: DTNH22 13 R 00705 Agency: DOT/National Highway Traffic Safety Administration Category: Health Funding Amount: $90,000 |
| FY13 State Partnership Grant Program to Improve Minority Health Apply for MP STT 13 001 Funding Number: MP STT 13 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $150,000 |
| Part C Capacity Development Program Apply for HRSA 13 169 Funding Number: HRSA 13 169 Agency: Health Resources and Services Administration Category: Health Funding Amount: $100,000 |
| Cooperative Agreements for Electronic Health Record (EHR) and Prescription Drug Monitoring Program (PDMP) Data Integration Apply for TI 13 013 Funding Number: TI 13 013 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $212,500 |
| State Implementation Grants for Improving Services for Children and Youth with Autism Spectrum Disorder and other Developmental Disabilities Apply for HRSA 13 207 Funding Number: HRSA 13 207 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| State Planning Grants for Improving Services for Children and Youth with Autism Spectrum Disorder and other Developmental Disabilities Apply for HRSA 13 200 Funding Number: HRSA 13 200 Agency: Health Resources and Services Administration Category: Health Funding Amount: $75,000 |
| State and Regional Approaches to Improving Access to Services for Children and Youths with Epilepsy Apply for HRSA 13 244 Funding Number: HRSA 13 244 Agency: Health Resources and Services Administration Category: Health Funding Amount: $390,536 |
| Tribal Self Governance Program, Negotiation Cooperative Agreement Apply for HHS 2013 IHS TSGN 0001 Funding Number: HHS 2013 IHS TSGN 0001 Agency: Indian Health Service Category: Health Funding Amount: $48,000 |
| Social and Behavioral Interventions to Increase Solid Organ Donation Apply for HRSA 14 014 Funding Number: HRSA 14 014 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Home Visiting Collaborative Improvement and Innovation Network (HV CoIIN) Apply for HRSA 13 284 Funding Number: HRSA 13 284 Agency: Health Resources and Services Administration Category: Health Funding Amount: $400,000 |
| Perinatal Infant Oral Health Quality Improvement (PIOHQI) Pilot Grant Program Apply for HRSA 13 283 Funding Number: HRSA 13 283 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "TI 13 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.